Surface Modification to Improve Cell Adhesion in Bioreactors
{'Code': '15030000', 'Directorate': {'Abbreviation': 'TIP', 'LongName': 'Dir for Tech, Innovation, & Partnerships'}, 'Division': {'Abbreviation': 'TI', 'LongName': 'Translational Impacts'}}
{'SignBlockName': 'Ritchie B. Coryell', 'PO_EMAI': None, 'PO_PHON': None}
Scientific and regulatory considerations dictate that many                      vaccines and genetically engineered proteins for use in humans                  are best prouced in mammalian cell lines derived from non-                      malignant sources.  These cells usually require a surface upon                  which to grow, and several bioreactor configurations have been                  developed which have large surface areas compressed into small                  volumes, thereby  improving the efficiency of the system.                       Currently, however, the internal surfaces are not adequate for                  long-term cell culture; the greatest problem is that cells                      typically die or detach after four to six weeks, thus greatly                   limiting the useful life of such bioreactors.                                                                                                                   Phase I will seek to covalently immobilize naturally occurring                  cell adhesion proteins onto surfaces suitable for large-scale                   cell culture, and then test their effectiveness in improving                    initial cell attachment, cell growth, and long-term viability                   using three representative cell lines.                                                                                                                          Phase II will seek to conduct more extensive long-term                          evaluations, test various cell lines, and investigate cell growth               in serum-free media.                                                                                                                                            Proof of concept of this technology should greatly improve the                  usefulness of bioreactors in producing certain proteins for                     pharmaceutical use.
{'FirstName': 'David', 'LastName': 'Clapper', 'PI_MID_INIT': 'L', 'PI_SUFX_NAME': None, 'PI_FULL_NAME': 'David L Clapper', 'EmailAddress': None, 'PI_PHON': '6128292700', 'NSF_ID': '000393028', 'StartDate': '02/01/1988', 'EndDate': None, 'RoleCode': 'Principal Investigator'}
{'Name': 'SurModics, Inc.', 'CityName': 'Eden Prairie', 'ZipCode': '553443523', 'PhoneNumber': '6128292707', 'StreetAddress': '9924 West Seventy Fourth Street', 'StreetAddress2': None, 'CountryName': 'United States', 'StateName': 'Minnesota', 'StateCode': 'MN', 'CONGRESSDISTRICT': '03', 'CONGRESS_DISTRICT_ORG': 'MN03', 'ORG_UEI_NUM': None, 'ORG_LGL_BUS_NAME': None, 'ORG_PRNT_UEI_NUM': None}
{'Name': None, 'CityName': None, 'StateCode': None, 'ZipCode': None, 'StreetAddress': None, 'CountryCode': None, 'CountryName': None, 'StateName': None, 'CountryFlag': None, 'CONGRESSDISTRICT': None, 'CONGRESS_DISTRICT_PERF': '""'}
{'Code': '5371', 'Text': 'SBIR Phase I'}
{'url': 'https://www.nsf.gov/awardsearch/download?DownloadFileName=1987&All=true', 'xml': '8760680.xml'}